Point Biopharma CEO Joe McCann and Lantheus CEO Mary Anne Heino
November 14, 2022 09:57 AM EST
Deals

Aim­ing at main­stream mar­kets, ra­dio­phar­ma­ceu­ti­cal part­ners en­gi­neer $260M cash deal

Amber Tong

When Point Bio­phar­ma geared up to launch a Phase III tri­al for its PS­MA-tar­get­ing ra­di­oli­gand ther­a­py, one of the first things it did was to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times